Mannkind (MNKD) logo

Mannkind (MNKD) stock

Disease medicines , market cap $1.3B

After-hours Fri
$3.93
+2.08%

Close $3.85 -2.53%

Quality Score
-4
Poor
In its industry
#64of 89
Checks firing
1of 14
Trending down
From 52-week high
-40.9%
under its best in a year

MNKD's Quality Score fell 3 points on Fri, Nov 20, to -4. Its price fell below its falling average of the last 200 days.

Follow MNKD's trial news. Pro members can get an alert when Mannkind files news, and see its trials, share raises, and its CEO's filings.

Get an alert when MNKD files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextEnd of 2026“On track for IND filing by year end”Filing with regulators · SEC filing · Aug 5
Cash$96.6M, about 5 quarters at the last year's spendingOn Sep 30

Why MNKD rose on Nov 6

Up 4% on Nov 6, and still 2% over its Nov 5 close.

  • It reported quarterly revenue of $101.9M and a diluted loss of $0.07 a share after the close on Nov 5.

Sources: Price history, Nov 6, 2026; SEC filing, Nov 5, 2026; Company release (8-K), Nov 5, 2026

Why MNKD still lags the market over five years

Down 17% over the five years to Nov 20 while the S&P 500 rose 58%; up 4% on Nov 6.

4 reasons, from its filings, with the timeline and its peers, for Pro members.

Key facts on MNKD

Key facts on MNKD
Since its 2024 highDown 47% profit $27.6M → a $74.8M loss a year
Latest filing10-Q, Nov 5 Filed its quarterly report (10-Q) for the quarter to Sep 30, 2026

MNKD in the news

Fri Nov 6Mannkind reported $101.9 million of quarterly revenue and a loss of $0.07 a share SEC, 4:03 PM ET MNKD closed +3.7% that day.

Cash$96.6M, about 5 quarters at the last year's spendingOn Sep 30

MNKD catalysts

Coming up

After its last 4 reports it closed -2.3% on average, higher 1 of 4 times.

11 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for MNKD, and how long its cash lasts

Next step the company has named

End of 2026“On track for IND filing by year end”Filing with regulators · SEC filing · Aug 5

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway
INHALE-1stPhase 2 · Recruiting · 100 people · main data estimated Mar 2027 · NCT07224321

1 more trial, 32 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 5 quarters

$96.6M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Feb 26, 2025)
  • At-the-market share sales program (S-3ASR, filed Feb 26, 2025)

For Pro members: the amounts, and the share count against a year ago.

Insiders

Director Steven B. Binder sold 39,051 shares on Sep 25, under a planned sale. 8 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Michael Castagna’s 20 filings and quotes.

Get an alert when MNKD files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why MNKD scores -4

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. MNKD scores -4 today, against a median of 0 over its last 20 recorded sessions.

  • +1Chart checks 1 of 14 firing right now, one point each
  • −3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Dilution, Persistence, and News.

What every line is worth, and the reason behind it, on MNKD and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when MNKD's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How MNKD ranks in Pharma

MNKD is #64 of 89 by Quality Score.

How MNKD ranks in Pharma
RankStockQuality Score
64Mannkind (MNKD) logoMNKDMannkind-4

More in Pharma

When does MNKD report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What MNKD reported on Nov 5, 2026

The quarter

Sales of $101.9M, 24% more than a year ago; a loss of $0.07 a share, from a profit of $0.03.

“The increase is primarily attributable to the inclusion of Furoscix into our product portfolio following the acquisition of scPharma in October 2025.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

Where the quarter's sales came from
LineQ3
2026
Q2
2026
Q3
2025
By product
Product revenueup 27%$61.5M37%$71.6M38%$48.3M37%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

4 more lines, for Pro members.

The outlook

No outlook figures read from this release.

The numbers

Market value
$1.3B
today
Sales
$413M
up 31.7% on the year
Free cash flow
-$78.4M
last 12 months

Sales grew 40% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 7.1% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on MNKD: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

-7.4%-0.3%-5.1%+3.7%
Feb 26May 6Aug 5Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close+4.3%+3.7%+10.6%
Aug 5, 2026After close-7.0%-5.1%-6.1%
May 6, 2026After close-6.7%-0.3%-9.8%
Feb 26, 2026Before open+5.7%-7.4%-15.7%

MNKD closed higher after 1 of its last 4 reports.

MNKD sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $349M. It made a profit in two of the eight years.

MNKD has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on MNKD, and all 14 on every stock.Get in free →See the top 3 →Start Pro

MNKD RSI on Nov 20: 52.1, above its 50-day and 200-day averages

Not scored

RSI 52.1, MACD below signal, above both averages. Not scored.

The deep dive on MNKD

8 more findings on MNKD, each with its source, for Pro members.

MNKD share count over time

4% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of MNKD outstanding, as filed
Shares
outstanding
As
of
321.6MOct 23, 2026
321.5MJul 24, 2026
309MApr 24, 2026
308.1MFeb 13, 2026
Offerings, shelves, and splits of MNKD, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Feb 26, 2025

MNKD's officers and directors

Officers and directors with a Form 4 in the last 12 months.

3 more officers and directors file at MNKD.

See insider trades by person

Which ETFs hold MNKD?

In ETFs: MNKD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Mannkind

MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

592 employeesDanbury, CTmannkindcorp.com

What Mannkind says it competes with

“The pharmaceutical and biotechnology industries are highly competitive and characterized by rapidly evolving technology and intense research and development efforts.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on MNKD and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn MNKD's score around: 8 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: MNKD's Quality Score is -4 (Poor), #64 of 89 in Pharma.

What does MNKD's Quality Score say?

MNKD scores -4 today, which Breakaway calls Poor. It is #64 of 89 in Pharma by Quality Score, with 1 of 14 chart checks firing. Up 4% on Nov 6, and still 2% over its Nov 5 close. Cash lasts about 5 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is MNKD's Quality Score?

MNKD scores -4 today, which Breakaway calls Poor (below zero). That is #64 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MNKD's -4.

When does MNKD report earnings?

Expected to report Thu Feb 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. MNKD closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Mannkind: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.